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Abstract
Background: This analysis was undertaken to evaluate the practice patterns of Japanese physicians regarding
curative-intent chemotherapy, especially in outpatient settings, and to define factors negatively affecting the
maintenance of relative dose intensity (RDI).
Methods: We performed a web-based questionnaire survey of Japanese physicians involved in malignant
lymphoma chemotherapy (Group ML) or in breast cancer chemotherapy (Group BC). The questionnaire inquired
how they manage low-risk febrile neutropenia (FN) caused by initial chemotherapy for diffuse large B-cell
lymphoma(DLBCL) or by adjuvant chemotherapy for breast cancer in an outpatient setting.
Results: Valid responses were obtained from 185 physicians in Group ML and 160 in Group BC. In Group ML, 76 %
(n = 141) of the physicians were board-certified hematologists, while 82 % (n = 131) of the physicians in Group BC
were board-certified surgeons. A significantly higher proportion of physicians in Group ML responded that “dose
reduction is not required for the subsequent course of chemotherapy after the first episode of FN” than in Group
BC (ML versus BC; 77 % versus 31 %; P < 0.001). Significantly higher proportions of physicians in Group ML were
more likely to prophylactically administer antibiotics or granulocyte-colony stimulating factor (G-CSF; ML versus BC;
antibiotics: 36 % versus 26 %, P = 0.049; G-CSF: 25 % versus 16 %, P = 0.047). Eighty six percent (n = 159) of Group
ML and 70 % (n = 112) of Group BC responded that “emergency outpatient unit is open at all hours”.
Conclusions: Japanese physicians are more likely to administer reduced doses of chemotherapy to patients with
breast cancer than to patients with malignant lymphoma. Supportive infrastructures should be improved to ensure
the provision of adequate chemotherapy to all cancer patients.
Background
Maintaining dose intensity is important for achieving the
full benefits of chemotherapy in patients with potentially
curable non-Hodgkin’s lymphoma and breast cancer. In
1990, Epelbaum et al. reported a strong association be-
tween the relative dose intensity (RDI) of a standard
CHOP (cyclophosphamide, doxorubicin, vincristine, pred-
nisone) regimen and 5-year survival among 95 patients
with diffuse large-cell lymphoma (DLCL) [1]. The 5-year
survival rate was 80 % in patients who received more than
the median average RDI, whereas it was only 32 % in those
who received less than the median average RDI (P <
0.001). Similarly, analysis of the RDIs of three
doxorubicin-based regimens (including CHOP) in 115 pa-
tients with DLCL revealed that RDI of doxorubicin greater
than 75 % was the most important predictor of survival
[2]. A recently published retrospective analysis by Bosly et
al. showed that survival of patients with diffuse large B-
cell lymphoma (DLBCL) improved with an increasing
average RDI (ARDI) of CHOP-21. Median survival was
7.08 years in those who received >90 % of the ARDI, sig-
nificantly longer than in those who received ≤90 % of the
ARDI (P = 0.002) [3]. In 1981, Bonadonna et al. reported a
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clear dose–response effect for CMF (cyclophosphamide,
methotrexate, and 5-fluorouracil [5-FU]) chemotherapy in
449 women with breast cancer [4]. Their results showed
that patients receiving ≥85 % of the planned CMF dose
had a 5-year relapse-free survival (RFS) rate of 77 %, com-
pared with 48 % in patients receiving <65 % of the planned
dose. In 1995, 20-year follow-up data from the same
group confirmed that RFS and overall survival (OS) were
substantially better in patients who received ≥85 % of their
planned dose than in those who received lower doses [5].
In 1998, Budman et al. reported the results of a random-
ized trial of adjuvant CAF (cyclophosphamide, doxorubi-
cin, 5-FU) for stage II breast cancer patients. In total,
1,550 breast cancer patients were randomly assigned to
one of three treatment arms: high-, moderate-, or low-
dose intensity treatments [6]. The results revealed that the
patients who received high- or moderate-dose inten-
sity had significantly longer disease-free survival (P <
0.001) and OS (P = 0.004) than those who received
low-dose intensity.
Recently, some study protocols specify that patients
who have an initial episode of febrile neutropenia (FN)
should additionally receive granulocyte-colony stimulat-
ing factor (G-CSF) or prophylactic antibiotics in subse-
quent cycles, and dose modification of chemotherapy is
unnecessary [7–9]. If there is a second FN episode des-
pite G-CSF or antibiotic support, the protocols recom-
mend a reduction in chemotherapy dose.
However, studies of patients with aggressive non-
Hodgkin’s lymphoma and early-stage breast cancer in
the United States have reported that nearly half of such
patients receive reduced dose-intensity chemotherapy
[10, 11]. Additionally, how Japanese physicians manage
outpatient chemotherapy and apply supportive measures
to maintain RDI remains largely unknown. In Japan,
chemotherapy for malignant lymphoma has been trad-
itionally administered by hematologists, while chemo-
therapy for breast cancer is administered mainly by
surgeons. This study was designed to clarify physicians’
attitudes and practice patterns with respect to curative-
intent chemotherapy and to define factors that nega-
tively affect RDI maintenance in Japan.
Methods
We posted a questionnaire on a Japanese web site for
physicians. Registration was required to access the ques-
tionnaire and those who completed the questionnaire
could receive points from the web site as an incentive.
The target respondents were physicians involved in the
treatment of malignant lymphoma (Group ML) and those
involved in the treatment of breast cancer (Group BC).
Respondents in Group ML had to: 1) be a member of the
Japanese Society of Hematology; 2) work at a hospital with
more than 20 beds; 3) attend more than five patients with
Non-Hodgkin’s lymphoma who receive chemotherapy;
and 4) attend at least one patient who received R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) in the past year. Respondents in Group BC
had to: 1) be a member of the Japanese Breast Cancer
Society; and 2) attend more than 15 patients who received
neoadjuvant or adjuvant chemotherapy in the past year.
The number of current members of the Japanese Society
of Hematology is around 6,400, whereas number of
current members of the Japanese Breast Cancer Society is
around 9,800, 68 % of which are surgeons.
In the questionnaire, we described a patient who re-
ceived first-line chemotherapy for DLBCL in Group ML
and a patient who received adjuvant chemotherapy for
early breast cancer in Group BC. In the clinical scenarios,
the patients suffer from low risk FN with The Multi-
national Association for Supportive Care in Cancer
(MASCC) scores ≥21 [12, 13] and in Talcott group 4 [14].
The questionnaire inquired about the management of FN
and subsequent cycles of chemotherapy. The questions
asked in the survey are listed in Table 1. This survey was
administered in Japanese. The surveillance period was
from November 30 through December 11, 2012.
All survey data were coded and analyzed with the use of
standard EZR (Saitama Medical Center, Jichi Medical
University), which is a graphical user interface for R (The
R Foundation for Statistical Computing, version 2.13.0)
[15]. More precisely, it is a modified version of R com-
mander (version 1.6–3) that includes statistical functions
that are frequently used in biostatistics. For comparisons
of categorical variables, Fisher’s exact tests were used.
The execution of the survey followed the ethical princi-
ples outlined in the Declaration of Helsinki regarding
human clinical research. The approval of the Ethics
Committee of Nippon Medical School Musashikosugi Hos-
pital was not required. This is because the regulation of the
Ethics Committee of Nippon Medical School does not
stipulate that a questionnaire survey for physicians requires
ethical committee approval. Moreover, this is an anonymous
questionnaire survey and we only use pseudonymized data.
Results
Table 2 lists the participant characteristics. Valid responses
were obtained from 185 respondents in Group ML and
160 in Group BC; there were no invalid responses. In
Group ML, 76 % (n = 141) of the respondents were board-
certified hematologists, and 10 % (n = 18) were board-
certified oncologists. In Group BC, 82 % (n = 131) were
board-certified surgeons and 36 % (n = 58) were board-
certified breast surgeons. Overall, 11 % (n = 17) of the re-
spondents in Group BC were board-certified oncologists.
In Group ML, 32 % (n = 59) of the respondents were
working at academic medical centers, 32 % (n = 59) at can-
cer centers or public hospitals, and 36 % (n = 67) at private
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Table 1 Questions asked in the survey


























Q. Please select one of the following to indicate your place of
employment.
1. Academic medical center
2. Cancer center or public hospital
3. Private hospital
4. Other
Diffuse large B-cell lymphoma (DLBCL)
A 68-year-old woman was given a diagnosis of DLBCL, Stage IV A.
There were hepatic metastases, but no bone marrow infiltration.
She had no clinically significant past medical history. The International
Prognostic Index was high-intermediate risk. Performance status (PS)
was 0. Lactate dehydrogenase (LDH) was 1,250 IU/L. She was scheduled
to receive six cycles of R-CHOP (rituximab 375 mg/m2 on day 1 or day
2, cyclophosphamide 750 mg/m2 on day 1, doxorubicin 50 mg/m2 on
day 1, vincristine 1.4 mg/m2 on day 1 [max 2 mg], prednisone 100 mg
on days 1–5) given every 21 days.
Breast cancer
A 68-year-old postmenopausal woman was given a diagnosis of right
breast cancer, cT2N0M0 stage II A. She had no clinically significant past
medical history. PS was 0. Right total mastectomy was performed.
Pathological findings were as follows: pT 2.0 cm, grade 3, ly-, v-, pN1
(3/20), ER(-), PgR(-), HER2(-). She was scheduled to receive four cycles
of TC (docetaxel 75 mg/m2 on day 1, cyclophosphamide 600 mg/m2
on day 1) given every 21 days.
Table 1 Questions asked in the survey (Continued)
Q1. Would you manage low-risk febrile neutropenia in patients such
as those describe above on an inpatient or outpatient basis?
1. Outpatient
2. Inpatient
Q2. (For those who chose outpatient management) Which of the
following choices do you feel most closely describes the treatment
you usually provide to this type of patient?
1. Oral antibiotics only
2. Oral antibiotics and G-CSF
3. Observation
4. Other
Q3. (For those who chose inpatient management) Which of the
following choices do you feel most closely describes the treatment
you usually provide to this type of patient?
1. Intravenous antibiotics
2. Intravenous antibiotics and G-CSF
3. Other
[Clinical Course]
On the tenth day of the first cycle, she presented with a fever of 39 °C.
A systematic review was unrevealing. Dietary and fluid intake was
sufficient.
Blood pressure, 135/80 mmHg
HEENT: She had a clear oropharynx.
Chest: No rales or wheezes were present.
Cardiac: Normal S1 and S2. There was no murmur.
Abdomen: Soft and flat. Bowel sounds were normal.
Laboratory data: WBC:1,200/mm3, ANC:400/mm3, Hb:11.4 g/dL,
PLT:158,000, GOT:23 IU/L, Alb:3.6 g/dL, BUN:18.8 mg/dL, Cr:0.6 mg/dL,
CRP:1.8 mg/dL
Q4. How do you modify the dose of subsequent courses of
chemotherapy after febrile neutropenia? Please select one of the
following options.
1. Dose reduction is not required
2. Dose reduction is required if febrile neutropenia was treated by
intravenous antibiotics
3. Dose reduction is required at any rate
4. Other
Q5. How do you use antibiotics for the subsequent course of
chemotherapy after febrile neutropenia? Please select one of the
following options.
1. Antimicrobial prophylaxis deserves consideration
2. Antibiotics should be taken into account when the next episode
of febrile neutropenia occurs
3. I typically do not administer antibiotics
4. Other
Q6. How do you use G-CSF for the subsequent course of chemotherapy
after febrile neutropenia? Please select one of the following options.
1. G-CSF prophylaxis deserves consideration
2. G-CSF should be taken into account when neutropenia occurs
3. G-CSF should be taken into account when the next episode of febrile
neutropenia occurs
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hospitals. In Group BC, 21 % (n = 33) were working at
academic medical centers, 29 % (n = 46) at cancer centers
or public hospitals, and 43 % (n = 69) at private hospitals.
Table 3 summarizes how the respondents manage low-
risk FN. 50 % (n = 93) of the physicians in Group ML
chose outpatient treatment for FN as compared with
65 % (n = 104) in Group BC (P = 0.006). Among the re-
spondents who chose outpatient treatment, a higher
proportion of physicians chose both oral antibiotics and
G-CSF in Group ML than in Group BC (82 % versus
53 %, P < 0.001). However, intravenous antibiotics and
G-CSF were preferred among physicians who chose in-
patient treatment for FN.
Table 4 summarizes how the respondents modify the
dose of chemotherapy in patients who have FN and their
attitudes toward the use of antibiotics and G-CSF for
subsequent cycles of chemotherapy. In Group ML, 77 %
(n = 143) of the physicians responded that “dose reduc-
tion is not required” compared with 31 % (n = 49) in
Group BC (P < 0.001). In Group BC, approximately one
third of the physicians responded that “dose reduction is
required if FN was treated by intravenous antibiotics”
and another third responded that “dose reduction is re-
quired at any rate”. Thirty-six percent (n = 67) of Group
ML and 26 % (n = 42) of Group BC responded that “anti-
microbial prophylaxis deserves consideration” (P = 0.049).
Approximately half of the physicians in each group
responded that “antibiotics are taken into account on the
next episode of FN”. Twenty-five percent (n = 47) of
Group ML and 16 % (n = 26) of Group BC responded that
“G-CSF prophylaxis deserves consideration” (P = 0.047).
Approximately half of the physicians in each group
responded that “G-CSF is taken into account when
Table 1 Questions asked in the survey (Continued)
4. I typically do not administer G-CSF
5. Other
Q7. Regarding systems for managing adverse effects of outpatient
chemotherapy, please check all appropriate responses.
1. Emergency outpatient unit is open at all hours
2. Clinical laboratory is open at all hours
3. Diagnostic imaging unit is open at all hours
4. Hospital antibiogram is available
5. Health professionals provide patient and family education
6. Chemotherapy telephone helpline is available
7. Not applicable
Table 2 Demographic characteristics of respondents
Characteristic Group ML (n = 185) Group BC (n = 160)
Number % Number %
Age (years) ≤29 5 3 ≤29 1 1
30–34 22 12 30–34 12 8
35–39 30 16 35–39 33 21
40–44 37 20 40–44 31 19
45–49 43 23 45–49 39 24
50–54 28 15 50–54 23 14
55–59 13 7 55–59 16 10
≥60 7 4 ≥60 5 3
Decade of medical license 2000s 44 24 2000s 33 21
1990s 88 48 1990s 72 45
1980s 46 25 1980s 46 29
1970s 7 4 1970s 9 6
Specialty Board-certified internist 142 77 Board-certified surgeon 131 82
Board-certified hematologist 141 76 Board-certified breast surgeon 58 36
Board-certified oncologist 18 10 Board-certified oncologist 17 11
Not applicable 15 8 Board-certified internist 10 6
Not applicable 8 5
Type of clinic/hospital Academic medical center 59 32 Academic medical center 33 21
Cancer center or public hospital 59 32 Cancer center or public hospital 46 29
Private hospital 67 36 Private hospital 69 43
Other 0 0 Other 12 8
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Table 3 Management of low-risk febrile neutropenia
Group ML Group BC
(n = 185) (n = 160)
Number % Number % P-value
Q. Inpatient versus outpatient management
Outpatient 93 50 104 65 P = 0.006
Inpatient 92 50 56 35 P = 0.006
Total 185 100 160 100
Q. (For those who chose outpatient management) Treatment of FN
Oral antibiotics only 14 15 47 45 P < 0.001
Oral antibiotics and G-CSF 76 82 55 53 P < 0.001
Observation 0 0 2 2 P = 0.499
Other 3 3 0 0 P = 0.103
Total 93 100 104 100
Q. (For who choose inpatient management) Treatment of FN
Intravenous antibiotics only 9 10 5 9 P = 1
Intravenous antibiotics and G-CSF 83 90 51 91 P = 1
Other 0 0 0 0 P = 1
Total 92 100 56 100
Abbreviations: FN febrile neutropenia
Table 4 Management of subsequent cycles of chemotherapy after low-risk FN
Group ML (n = 185) Group BC (n = 160)
Number % Number % P-value
Q. Dose of chemotherapy
Dose reduction is not required 143 77 49 31 P < 0.001
Dose reduction is required if febrile neutropenia
was treated by intravenous antibiotics
18 10 56 35 P < 0.001
Dose reduction is required at any rate 22 12 55 34 P < 0.001
Other 2 1 0 0 P = 0.501
Total 185 100 160 100
Q. Antibiotics
Antimicrobial prophylaxis deserves consideration 67 36 42 26 P = 0.049
Antibiotics are taken into account on the next
episode of febrile neutropenia
91 49 95 59 P = 0.065
I typically don’t administer antibiotics 27 15 23 14 P = 1
Other 0 0 0 0 P = 1
Total 185 100 160 100
Q. G-CSF
G-CSF prophylaxis deserves consideration 47 25 26 16 P = 0.047
G-CSF is taken into account when neutropenia occurs 114 62 75 47 P = 0.006
G-CSF is taken into account on the next episode of
febrile neutropenia
15 8 46 29 P < 0.001
I typically don’t administer G-CSF 7 4 13 8 P = 0.107
Other 2 1 0 0 P = 0.501
Total 185 100 160 100
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neutropenia occurs”. About one third of Group BC
responded that “G-CSF is taken into account when the
next episode of FN occurs”.
Table 5 shows the details of the systems used to manage
adverse effects of outpatient chemotherapy. For this ana-
lysis, physicians who work at clinics with less than 12 beds
were not included in Group ML, but were included in
Group BC. Eight percent (n = 12) of physicians in Group
BC worked at clinics with less than 20 beds. Eighty-six
percent (n = 159) of Group ML and 70 % (n = 112) of
Group BC responded that the “emergency outpatient unit
is open at all hours”. Sixty-nine percent (n = 128) of Group
ML and 41 % (n = 66) of Group BC responded that the
“clinical laboratory is open at all hours”. Moreover, 63 %
(n = 117) of Group ML and 33 % (n = 52) of Group BC
responded that the “diagnostic imaging unit is open at all
hours”. Only 15 % (n = 27) of physicians in Group ML and
16 % (n = 26) of those in Group BC group responded that
a “chemotherapy telephone helpline is available”.
Discussion
The most important finding of our study is that many
Japanese physicians reduce the dose of chemotherapeu-
tic agents after the first episode of low-risk FN in pa-
tients with potentially curable aggressive non-Hodgkin’s
lymphoma or early-stage breast cancer. In the question-
naire, we presented the case of a patient who had FN
during treatment for aggressive non-Hodgkin’s lymph-
oma or early-stage breast cancer in an outpatient setting
(Table 1). She was clinically stable without significant
medical comorbidity on presentation. Her MASCC score
[12, 13] was 24, and she was classified as Talcott’s Group 4
[14], indicating low-risk FN. As for the subsequent course
of chemotherapy, a higher proportion of physicians in
Group BC responded that “dose reduction is required at
any rate” or that “dose reduction is required if FN was
treated by intravenous antibiotics” than in Group ML.
As mentioned in the introduction, there is well-
established evidence supporting the clinical significance
of RDI and its impact on survival in patients with
aggressive non-Hodgkin’s lymphoma or early stage
breast cancer [1–6]. This is why reducing the dose and
delaying chemotherapy should be avoided. FN and
severe prolonged neutropenia can lead to the decision to
reduce chemotherapy dose and delay subsequent treat-
ment cycles. In addition, the risk of fatal infection rises
as the absolute neutrophil count falls below 500/mm3
and is higher in those with a prolonged neutropenia dur-
ation (>7 days) [16]. Therefore, management of afebrile
and febrile neutropenia is significant. The Cochrane
Haematological Malignancies Group published a review
that compare the effectiveness of prophylactic adminis-
tration of G-CSF or Granulocyte Macrophage Colony-
Stimulating Factor (GM-CSF) with antibiotics in cancer
patients receiving chemotherapy [17]. Two randomized
controlled trials were eligible. This review showed non-
significant results favoring antibiotics for preventing fever
or hospitalization for FN compared with G-CSF. However,
in one of the two trials, the chemotherapy dose intensity
received by the antibiotic comparison group was much
lower than in the GM-CSF group [18], which may explain
the increased incidence of infections in the GM-CSF
group. A non-randomized comparison within a random-
ized controlled trial (GEPARTRIO study) lead to a differ-
ent outcome [19]. In breast cancer patients receiving TAC
(docetaxel, doxorubicin and cyclophosphamide) pegfil-
grastim alone or pegfilgrastim plus antibiotics provided
suboptimal protection against FN and antibiotics alone
was least effective.
Our results showed that that G-CSF and antibiotics
are not commonly administered as prophylaxis against
FN by Japanese physicians. G-CSF use for the manage-
ment of established afebrile neutropenia was preferred
in both groups. Guidelines recommend against the use
of G-CSF in patients with afebrile neutropenia [20–23].
A randomized, double blind, placebo-controlled trial of
G-CSF has been performed in afebrile outpatients with
severe chemotherapy-induced neutropenia [24]: G-CSF
Table 5 System for managing adverse effects during outpatient chemotherapy
Group ML (n = 185) Group BC (n = 160)
Number % Number % P-value
Q. Regarding the system for managing adverse effects of outpatient chemotherapy,
please check all appropriate responses
Emergency outpatient unit is open at all hours 159 86 112 70 P < 0.001
Clinical laboratory is open at all hours 128 69 66 41 P < 0.001
Diagnostic imaging unit is open at all hours 117 63 52 33 P < 0.001
Hospital antibiogram is available 105 57 40 25 P < 0.001
Health professions provide patient and family education 81 44 52 33 P = 0.035
Chemotherapy telephone helpline is available 27 15 26 16 P = 0.765
Not applicable 0 0 11 7 P < 0.001
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shortened the duration of neutropenia, but did not
decrease the hospitalization rate for FN, length of hos-
pital stay, the number of days of antibiotic therapy, and
the likelihood of having a positive culture.
Guidelines support the use of G-CSF in patients with
FN who are at high risk for infection-associated compli-
cations [20–23]. A randomized, open-label, non-
placebo-controlled trial has evaluated the effectiveness
of adding G-CSF to antibiotic therapy in patients with
solid tumors and chemotherapy-induced high-risk FN
[25]. Adding G-CSF to antibiotic therapy was found to
shorten the duration of neutropenia and reduce the dur-
ation of antibiotic therapy and hospitalization, but the
treatment success rate, time to fever resolution, and
mortality rate were similar in both treatment arms. Con-
trary to such evidence, many physicians use G-CSF with
therapeutic intent.
In Japan, the majority of cancer care, including chemo-
therapy for solid tumors, has been historically performed
by surgeons. Moreover, there is a shortage of medical
oncologists in Japan. As of 2015, only 954 physicians
have become Board-Certified Medical Oncologists of the
Japanese Society of Medical Oncology (JSMO) [26].
Oncology education and training system in Japan needs
much improvement. In addition, pegfilgrastim was not
available in Japan until November 2014, and hospital
visits on successive days were required. These factors
may have a negative impact on outpatient management
of chemotherapy and supportive care.
The Japanese Breast Cancer Society has developed
Clinical Practice Guidelines for the systemic treatment
of breast cancer [27]. These guidelines do not report
how to use G-CSF or antibiotics as curative-intent
chemotherapy. Including information about RDI and
supportive measures into these guidelines may be an
effective way to improve maintenance of dose-intensity.
About 50 % of Group ML and 35 % of Group BC
chose to have the patient admitted to hospital for the
treatment of FN. The American Society of Clinical On-
cology (ASCO) clinical practice guidelines recommends
outpatient management of low-risk FN as an option for
carefully selected patients [28]. Based on the ASCO’s
members’ expert opinion, “access to a telephone and
transportation 24 h a day” is one of the requirements for
outpatient treatment. However, our survey revealed that
support systems for outpatient chemotherapy have not
been adequately established in many hospitals and
clinics in Japan.
Our study has several important limitations. First, the
respondents may have been forgetful or may have
responded without understanding the full context of the
situation presented in the survey. In addition, eligible re-
spondents were limited to physicians who had access to
the website, potentially introducing self-selection bias.
Despite these limitations, we believe that our study rep-
resents an important step in the improvement of cancer
chemotherapy in Japan.
Conclusions
In summary, our results suggest that supportive mea-
sures to deliver full dose-intensity chemotherapy are not
widely used by Japanese physicians. Systems to support
outpatient chemotherapy should thus be improved.
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